X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition provides Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead MB272, is a selective agonist of immune inhibitory receptor B and T-Lymphocyte Attenuator.
Lead Product(s): MB272
Therapeutic Area: Immunology Product Name: MB272
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $405.0 million Upfront Cash: $405.0 million
Deal Type: Acquisition September 20, 2022
Details:
The acquisition will provide Gilead, MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator.
Lead Product(s): MB272
Therapeutic Area: Immunology Product Name: MB272
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $405.0 million Upfront Cash: $405.0 million
Deal Type: Acquisition August 04, 2022
Details:
Funds will primarily be used to advance MiroBio’s two lead antibody candidates into clinical trials and obtain safety and efficacy data in patients with autoimmune diseases. MB272 and MB151 are differentiated, precision-engineered checkpoint receptor agonists for BTLA & PD-1.
Lead Product(s): MB272
Therapeutic Area: Immunology Product Name: MB272
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Medicxi
Deal Size: $97.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 29, 2022
Details:
The company’s lead program, MB272, targets the immune receptor B- and T-lymphocyte attenuator and advance pipeline of checkpoint agonist antibodies designed to treat autoimmune disease.
Lead Product(s): MB272
Therapeutic Area: Immunology Product Name: MB272
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
